ABSTRACT
BACKGROUND: High-flow nasal oxygen therapy (HFNOT) therapy has been increasingly used in patients with acute hypoxemic (Type I) respiratory failure (RF). Meanwhile indications and clinical effectiveness of HFNOT in patients with hypercapnic (Type II) RF remain controversial. The aim of our study was to evaluate the outcomes of primary HFTNOT in patients with hypoxemic and hypercapnic RF. MATERIALS AND METHODS: We conducted a retrospective observational study of patients diagnosed with severe community acquired pneumonia (CAP), who required HFNC oxygen therapy for hypoxemia. Primary end-point was intubation or escalation to NIV rate after HFNOT. The secondary endpoint was the 30-day mortality after an admission regardless of the cause. RESULTS: Analysis was conducted on all 51 (n = 51) patients. Of these, 32 (63%) were diagnosed with Type I RF and 19 (37%) with Type II RF. The partial pressure of arterial carbon dioxide (PaCO2) in Type I RF patients was 34.05 mmHg at admission and decreased to 33.07 mmHg after 1 hour of HFNOT. In patients with Type II RF PaCO2 decreased from 56.47 to 54.97 mmHg. In Type I RF successful outcome was achieved in 25 patients (78%) compared to 11 patients (58%) with Type II RF. Escalation was required in seven patients with Type I RF and eight patients in Type II group. There were no mortalities in our population group. CONCLUSIONS: Our data suggest that HFNOT can be effectively used in Type I and Type II RF. Clinicians should be cautious identifying patients at risk of escalation. A larger population group study is needed to identify predictors of HFNOT failure.
ABSTRACT
INTRODUCTION: Malignant otitis externa (MOE) is a potentially life-threatening infection of the soft tissues of the external ear, quickly spreading to involve the periosteum and bone of the skull base. Treatment includes antibiotics and eventually surgery. Hyperbaric oxygen treatment (HBOT) has been proposed as an adjunctive therapy. However, in the tenth consensus conference, this disease was considered as a non-indication for HBOT. The aim of this study was to evaluate the effectiveness of HBOT in MOE treatment. METHODS: Retrospective and observational study was conducted of patients with MOE treated in our centre. Staging of the disease was made according to the clinicopathological classification system. RESULTS: From March 1998 to November 2016, 16 patients were referred. 6% patients were on stage 1 of the disease at the time they were referred, 20% in stage 2, 7% in stage 3a, 13% in stage 3b and 53% in stage 4. Seven (43.75%) patients had VII nerve palsy and three (18.75%) patients had multiple nerve palsy. Average length of symptoms of disease was 5 months (maximum 11 months). Average number of sessions was 33 and the length of hospitalization prior to HBOT (median 90 days) was significantly longer than the time between beginning HBOT and cure (p = 0.028, Wilcoxon signed rank test). There were no fatalities due to MOE and all patients were considered free of disease after HBOT. CONCLUSION: HBOT was well tolerated and revealed to be a helpful adjuvant treatment in MOE. According to our data, HBOT should be considered for patients who failed conventional treatments and in severe cases.
